Annual Total Liabilities
$39.78 M
+$13.64 M+52.19%
December 31, 2023
Summary
- As of February 22, 2025, AVIR annual total liabilities is $39.78 million, with the most recent change of +$13.64 million (+52.19%) on December 31, 2023.
- During the last 3 years, AVIR annual total liabilities has fallen by -$276.06 million (-87.41%).
- AVIR annual total liabilities is now -87.41% below its all-time high of $315.83 million, reached on December 31, 2020.
Performance
AVIR Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$32.44 M
-$1.48 M-4.36%
September 30, 2024
Summary
- As of February 22, 2025, AVIR quarterly total liabilities is $32.44 million, with the most recent change of -$1.48 million (-4.36%) on September 30, 2024.
- Over the past year, AVIR quarterly total liabilities has increased by +$6.09 million (+23.12%).
- AVIR quarterly total liabilities is now -89.73% below its all-time high of $315.83 million, reached on December 31, 2020.
Performance
AVIR Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
AVIR Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +52.2% | +23.1% |
| 3 y3 years | -87.4% | +23.1% |
| 5 y5 years | -44.0% | +23.1% |
AVIR Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -36.7% | +52.2% | -48.4% | +62.6% |
| 5 y | 5-year | -87.4% | +52.2% | -89.7% | +355.1% |
| alltime | all time | -87.4% | +52.2% | -89.7% | +355.1% |
Atea Pharmaceuticals Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $32.44 M(-4.4%) |
| Jun 2024 | - | $33.91 M(-30.3%) |
| Mar 2024 | - | $48.66 M(+22.3%) |
| Dec 2023 | $39.78 M(+52.2%) | $39.78 M(+51.0%) |
| Sep 2023 | - | $26.34 M(+11.3%) |
| Jun 2023 | - | $23.68 M(+18.7%) |
| Mar 2023 | - | $19.95 M(-23.7%) |
| Dec 2022 | $26.14 M | $26.14 M(+11.7%) |
| Sep 2022 | - | $23.39 M(-31.0%) |
| Jun 2022 | - | $33.88 M(-9.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | $37.30 M(-40.6%) |
| Dec 2021 | $62.81 M(-80.1%) | $62.81 M(-76.0%) |
| Sep 2021 | - | $262.05 M(-4.2%) |
| Jun 2021 | - | $273.68 M(+7.6%) |
| Mar 2021 | - | $254.39 M(-19.5%) |
| Dec 2020 | $315.83 M(+340.8%) | $315.83 M(+69.2%) |
| Sep 2020 | - | $186.62 M(+2518.5%) |
| Jun 2020 | - | $7.13 M(-90.1%) |
| Dec 2019 | $71.64 M(+0.9%) | $71.64 M |
| Dec 2018 | $71.02 M | - |
FAQ
- What is Atea Pharmaceuticals annual total liabilities?
- What is the all time high annual total liabilities for Atea Pharmaceuticals?
- What is Atea Pharmaceuticals annual total liabilities year-on-year change?
- What is Atea Pharmaceuticals quarterly total liabilities?
- What is the all time high quarterly total liabilities for Atea Pharmaceuticals?
- What is Atea Pharmaceuticals quarterly total liabilities year-on-year change?
What is Atea Pharmaceuticals annual total liabilities?
The current annual total liabilities of AVIR is $39.78 M
What is the all time high annual total liabilities for Atea Pharmaceuticals?
Atea Pharmaceuticals all-time high annual total liabilities is $315.83 M
What is Atea Pharmaceuticals annual total liabilities year-on-year change?
Over the past year, AVIR annual total liabilities has changed by +$13.64 M (+52.19%)
What is Atea Pharmaceuticals quarterly total liabilities?
The current quarterly total liabilities of AVIR is $32.44 M
What is the all time high quarterly total liabilities for Atea Pharmaceuticals?
Atea Pharmaceuticals all-time high quarterly total liabilities is $315.83 M
What is Atea Pharmaceuticals quarterly total liabilities year-on-year change?
Over the past year, AVIR quarterly total liabilities has changed by +$6.09 M (+23.12%)